{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:35:32Z","timestamp":1790660132873,"version":"4.1.0"},"reference-count":111,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:00:00Z","timestamp":1787184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Diabetic cardiomyopathy refers to myocardial structural, functional, and metabolic abnormalities enriched in people with diabetes that are not fully explained by obstructive epicardial coronary artery disease, significant valvular disease, or other established cardiac conditions. In clinical practice, diabetic myocardial dysfunction frequently overlaps with obesity, hypertension, chronic kidney disease, coronary microvascular dysfunction, and heart failure with preserved ejection fraction (HFpEF)-type cardiometabolic phenotypes. Among the mechanisms implicated in this condition, advanced glycation end products (AGEs) and receptor for advanced glycation end products (RAGE) signaling constitute a biologically plausible framework linking chronic hyperglycemia and dicarbonyl stress to myocardial injury. This review distinguishes RAGE-independent AGE-mediated injury, including extracellular matrix cross-linking and intracellular protein modification, from RAGE-dependent multiligand signaling, which may amplify oxidative, inflammatory, mitochondrial, calcium-handling, endothelial, and profibrotic responses. We further discuss RAGE as a multiligand pattern-recognition receptor and its interactions with danger signaling, innate immune pathways, and inflammasome activation within a broader inflammatory\u2013oxidative network. In addition, we evaluate therapeutic strategies aimed at reducing glycation burden, interrupting matrix cross-linking, or inhibiting receptor-related signaling, and assess circulating and tissue-related biomarkers for phenotypic stratification and therapeutic monitoring. The review further considers methylglyoxal, glyoxal, 3-deoxyglucosone, and glyoxalase-1-dependent detoxification as components of dicarbonyl stress. Although experimental evidence supports biological plausibility, human evidence remains predominantly associative, circulating biomarkers lack cardiac specificity, and DCM-specific therapeutic trials are scarce. Future studies should use phenotype-enriched, multimodal biomarker strategies and mechanism-matched endpoints to determine whether selected patient subgroups may benefit from AGE- or RAGE-directed intervention.<\/jats:p>","DOI":"10.3389\/fcvm.2026.1846184","type":"journal-article","created":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:30:16Z","timestamp":1787229016000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Advanced glycation end products and RAGE signaling in diabetic cardiomyopathy: distinct mechanisms, human evidence, and translational barriers"],"prefix":"10.3389","volume":"13","author":[{"given":"Zhiqiang","family":"Wang","sequence":"first","affiliation":[{"name":"Health Science Center, Yangtze University","place":["Jingzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbo","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoya","family":"Li","sequence":"additional","affiliation":[{"name":"Health Science Center, Yangtze University","place":["Jingzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muwei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Fuwai Central China Cardiovascular Hospital, Central China Fuwai Hospital of Zhengzhou University","place":["Zhengzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0002-9149(72)90595-4","article-title":"New type of cardiomyopathy associated with diabetic glomerulosclerosis","volume":"30","author":"Rubler","year":"1972","journal-title":"Am J Cardiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1161\/CIRCRESAHA.117.311586","article-title":"Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity","volume":"122","author":"Jia","year":"2018","journal-title":"Circ Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1136\/heartjnl-2016-310342","article-title":"Diabetic cardiomyopathy","volume":"105","author":"Lee","year":"2019","journal-title":"Heart"},{"key":"B4","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jacc.2017.11.019","article-title":"Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy","volume":"71","author":"Marwick","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1032268","DOI":"10.3389\/fendo.2022.1032268","article-title":"Diabetic cardiomyopathy: clinical phenotype and practice","volume":"13","author":"Zhao","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"133554","DOI":"10.1016\/j.ijcard.2025.133554","article-title":"Diabetic cardiomyopathy revisited: the interplay between diabetes and heart failure","volume":"438","author":"Mann","year":"2025","journal-title":"Int J Cardiol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1080\/13813455.2025.2567336","article-title":"Hyperglycaemia to heart failure: molecular pathophysiology, clinical manifestations, and novel therapeutic targets for diabetic cardiomyopathy","volume":"132","author":"Balakrishnan","year":"2026","journal-title":"Arch Physiol Biochem"},{"key":"B8","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/antiox11040784","article-title":"Role of oxidative stress in diabetic cardiomyopathy","volume":"11","author":"De Geest","year":"2022","journal-title":"Antioxidants"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1161\/CIRCRESAHA.120.315913","article-title":"Basic mechanisms of diabetic heart disease","volume":"126","author":"Ritchie","year":"2020","journal-title":"Circ Res"},{"key":"B10","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1038\/s41569-020-0339-2","article-title":"Mechanisms of diabetic cardiomyopathy and potential therapeutic strategies: preclinical and clinical evidence","volume":"17","author":"Tan","year":"2020","journal-title":"Nat Rev Cardiol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"659","DOI":"10.2337\/dbi23-0019","article-title":"Redefining diabetic cardiomyopathy: perturbations in substrate metabolism at the heart of its pathology","volume":"73","author":"Heather","year":"2024","journal-title":"Diabetes"},{"key":"B12","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1097\/CM9.0000000000003075","article-title":"Mitochondrial energy metabolism in diabetic cardiomyopathy: physiological adaption, pathogenesis, and therapeutic targets","volume":"137","author":"Ye","year":"2024","journal-title":"Chin Med J (Engl)"},{"key":"B13","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10719-025-10194-x","article-title":"Advanced glycation end products (AGEs) and their role in diabetes mellitus and related complications: mechanisms and therapeutic insights","volume":"42","author":"Qaed","year":"2025","journal-title":"Glycoconj J"},{"key":"B14","doi-asserted-by":"publisher","first-page":"120860","DOI":"10.1016\/j.lfs.2022.120860","article-title":"Aftermath of AGE-RAGE cascade in the pathophysiology of cardiovascular ailments","volume":"307","author":"Wasim","year":"2022","journal-title":"Life Sci"},{"key":"B15","doi-asserted-by":"publisher","first-page":"7311","DOI":"10.3390\/ijms26157311","article-title":"The role of advanced glycation end-products in the pathophysiology and pharmacotherapy of cardiovascular disease","volume":"26","author":"Mota","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B16","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.106.621854","article-title":"Advanced glycation end products: sparking the development of diabetic vascular injury","volume":"114","author":"Goldin","year":"2006","journal-title":"Circulation"},{"key":"B17","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.redox.2013.12.016","article-title":"Role of advanced glycation end products in cellular signaling","volume":"2","author":"Ott","year":"2014","journal-title":"Redox Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"125148","DOI":"10.1016\/j.ijbiomac.2023.125148","article-title":"Optimizing glycation control in diabetes: an integrated approach for inhibiting nonenzymatic glycation reactions of biological macromolecules","volume":"243","author":"Song","year":"2023","journal-title":"Int J Biol Macromol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1161\/CIRCULATIONAHA.107.728550","article-title":"Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension","volume":"117","author":"van Heerebeek","year":"2008","journal-title":"Circulation"},{"key":"B20","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1093\/eurjhf\/hfq168","article-title":"Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients","volume":"13","author":"Willemsen","year":"2011","journal-title":"Eur J Heart Fail"},{"key":"B21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fcvm.2020.00037","article-title":"Receptor for advanced glycation end products and mechanisms and therapeutic opportunities in diabetes and cardiovascular disease: insights from human subjects and animal models","volume":"7","author":"Ega\u00f1a-Gorro\u00f1o","year":"2020","journal-title":"Front Cardiovasc Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"107282","DOI":"10.1016\/j.phrs.2024.107282","article-title":"Activation and modulation of the AGEs-RAGE axis: implications for inflammatory pathologies and therapeutic interventions\u2014a review","volume":"206","author":"Zhou","year":"2024","journal-title":"Pharmacol Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/bs.vh.2024.04.005","article-title":"Glycation in the cardiomyocyte","volume":"125","author":"Delligatti","year":"2024","journal-title":"Vitam Horm"},{"key":"B24","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/ph18010134","article-title":"Critical appraisal of pharmaceutical therapy in diabetic cardiomyopathy\u2014challenges and prospectives","volume":"18","author":"Khattab","year":"2025","journal-title":"Pharmaceuticals"},{"key":"B25","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/414813a","article-title":"Biochemistry and molecular cell biology of diabetic complications","volume":"414","author":"Brownlee","year":"2001","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s001250051591","article-title":"Advanced glycation end-products: a review","volume":"44","author":"Singh","year":"2001","journal-title":"Diabetologia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"46","DOI":"10.3892\/br.2021.1422","article-title":"Toxicity of advanced glycation end products (review)","volume":"14","author":"Kuzan","year":"2021","journal-title":"Biomed Rep"},{"key":"B28","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2165\/00002512-199609020-00001","article-title":"Role of the maillard reaction in diabetes mellitus and diseases of aging","volume":"9","author":"Thorpe","year":"1996","journal-title":"Drugs Aging"},{"key":"B29","doi-asserted-by":"publisher","first-page":"109889","DOI":"10.1016\/j.cellsig.2020.109889","article-title":"Cross your heart? Collagen cross-links in cardiac health and disease","volume":"79","author":"Neff","year":"2021","journal-title":"Cell Signal"},{"key":"B30","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1007\/s00726-010-0783-0","article-title":"Methylglyoxal, glyoxalase 1 and the dicarbonyl proteome","volume":"42","author":"Rabbani","year":"2012","journal-title":"Amino Acids"},{"key":"B31","doi-asserted-by":"publisher","first-page":"15724","DOI":"10.3390\/ijms140815724","article-title":"Mild oxidative damage in the diabetic rat heart is attenuated by glyoxalase-1 overexpression","volume":"14","author":"Brouwers","year":"2013","journal-title":"Int J Mol Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1113\/EP090042","article-title":"AGEs-RAGE axis mediates myocardial fibrosis via activation of cardiac fibroblasts induced by autophagy in heart failure","volume":"107","author":"Liang","year":"2022","journal-title":"Exp Physiol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1159\/000364779","article-title":"Effects of advanced glycation end products on calcium handling in cardiomyocytes","volume":"129","author":"Yan","year":"2014","journal-title":"Cardiology"},{"key":"B34","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1006\/jmcc.2002.2084","article-title":"Advanced glycation endproduct-induced calcium handling impairment in mouse cardiac myocytes","volume":"34","author":"Petrova","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1002\/2211-5463.12284","article-title":"Advanced glycation end products reduce the calcium transient in cardiomyocytes by increasing production of reactive oxygen species and nitric oxide","volume":"7","author":"Hegab","year":"2017","journal-title":"FEBS Open Bio"},{"key":"B36","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1161\/01.RES.0000065620.39919.20","article-title":"A breaker of advanced glycation end products attenuates diabetes-induced myocardial structural changes","volume":"92","author":"Candido","year":"2003","journal-title":"Circ Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"H2587","DOI":"10.1152\/ajpheart.00516.2003","article-title":"Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart","volume":"285","author":"Liu","year":"2003","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"292","DOI":"10.3389\/fphys.2012.00292","article-title":"Advanced glycation end product cross-link breaker attenuates diabetes-induced cardiac dysfunction by improving sarcoplasmic reticulum calcium handling","volume":"3","author":"Kranstuber","year":"2012","journal-title":"Front Physiol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1046\/j.1365-2796.2002.00932.x","article-title":"Diabetes and advanced glycation end products","volume":"251","author":"Vlassara","year":"2002","journal-title":"J Intern Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s11892-013-0453-2","article-title":"Advanced glycation end products (AGE) and diabetes: cause, effect, or both?","volume":"14","author":"Vlassara","year":"2014","journal-title":"Curr Diab Rep"},{"key":"B41","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2021.05.025","article-title":"AGE\/RAGE in diabetic kidney disease and ageing kidney","volume":"171","author":"Wu","year":"2021","journal-title":"Free Radic Biol Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"13801","DOI":"10.1073\/pnas.0600362103","article-title":"Advanced glycation end product receptor 1 suppresses cell oxidant stress and activation signaling via EGF receptor","volume":"103","author":"Cai","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B43","doi-asserted-by":"publisher","first-page":"14998","DOI":"10.1016\/S0021-9258(18)42138-2","article-title":"Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins","volume":"267","author":"Neeper","year":"1992","journal-title":"J Biol Chem"},{"key":"B44","doi-asserted-by":"publisher","first-page":"BSR20193360","DOI":"10.1042\/BSR20193360","article-title":"The trp triad within the V-domain of the receptor for advanced glycation end products modulates folding, stability and ligand binding","volume":"40","author":"Indurthi","year":"2020","journal-title":"Biosci Rep"},{"key":"B45","doi-asserted-by":"publisher","first-page":"34457","DOI":"10.1074\/jbc.M801465200","article-title":"Interaction of the RAGE cytoplasmic domain with diaphanous-1 is required for ligand-stimulated cellular migration through activation of Rac1 and Cdc42","volume":"283","author":"Hudson","year":"2008","journal-title":"J Biol Chem"},{"key":"B46","first-page":"1699","article-title":"Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues","volume":"143","author":"Brett","year":"1993","journal-title":"Am J Pathol"},{"key":"B47","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1172\/JCI14002","article-title":"The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses","volume":"108","author":"Schmidt","year":"2001","journal-title":"J Clin Invest"},{"key":"B48","doi-asserted-by":"publisher","first-page":"18270","DOI":"10.1021\/jacs.4c01413","article-title":"Investigation of N-glycan functions in receptor for advanced glycation end products V domain through chemical glycoprotein synthesis","volume":"146","author":"Dong","year":"2024","journal-title":"J Am Chem Soc"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1016\/j.chembiol.2025.09.004","article-title":"RAGE-mediated activation of the formin DIAPH1 and human macrophage inflammation are inhibited by a small molecule antagonist","volume":"32","author":"Theophall","year":"2025","journal-title":"Cell Chem Biol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"eabf7084","DOI":"10.1126\/scitranslmed.abf7084","article-title":"Small-molecule antagonism of the interaction of the RAGE cytoplasmic domain with DIAPH1 reduces diabetic complications in mice","volume":"13","author":"Manigrasso","year":"2021","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.3390\/ijms23094579","article-title":"The RAGE\/DIAPH1 signaling axis and implications for the pathogenesis of diabetic complications","volume":"23","author":"Ramasamy","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B52","doi-asserted-by":"publisher","first-page":"H1026","DOI":"10.1152\/ajpheart.00685.2024","article-title":"Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts","volume":"328","author":"Yepuri","year":"2025","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1146\/annurev-med-041316-085215","article-title":"Targeting RAGE signaling in inflammatory disease","volume":"69","author":"Hudson","year":"2018","journal-title":"Annu Rev Med"},{"key":"B54","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.3390\/biom14121550","article-title":"Role of the receptor for advanced glycation end products and its ligands in inflammatory responses","volume":"14","author":"Cross","year":"2024","journal-title":"Biomolecules"},{"key":"B55","doi-asserted-by":"publisher","first-page":"767","DOI":"10.4049\/jimmunol.1900860","article-title":"Interplay between RAGE and TLR4 regulates HMGB1-induced inflammation by promoting cell surface expression of RAGE and TLR4","volume":"205","author":"Zhong","year":"2020","journal-title":"J Immunol"},{"key":"B56","doi-asserted-by":"crossref","first-page":"15659","DOI":"10.1096\/fj.202002136R","article-title":"The role of RAGE in host pathology and crosstalk between RAGE and TLR4 in innate immune signal transduction pathways","volume":"34","author":"Prantner","year":"2020","journal-title":"FASEB J"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.1002\/ehf2.14036","article-title":"Increased serum S100A12 levels are associated with higher risk of acute heart failure in patients with type 2 diabetes","volume":"9","author":"Gellen","year":"2022","journal-title":"ESC Heart Fail"},{"key":"B58","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1111\/febs.15723","article-title":"Heme & RAGE: a new opportunistic relationship?","volume":"288","author":"Yepuri","year":"2021","journal-title":"FEBS J"},{"key":"B59","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.1111\/febs.15667","article-title":"The receptor for advanced glycation end products is a sensor for cell-free heme","volume":"288","author":"May","year":"2021","journal-title":"FEBS J"},{"key":"B60","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1124\/jpet.123.002037","article-title":"Cannabinoid 2 receptor activation protects against diabetic cardiomyopathy through inhibition of AGE\/RAGE-induced oxidative stress, fibrosis, and inflammasome activation","volume":"391","author":"Hashiesh","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1359255","DOI":"10.3389\/fendo.2024.1359255","article-title":"Endothelial dysfunction in vascular complications of diabetes: a comprehensive review of mechanisms and implications","volume":"15","author":"Yang","year":"2024","journal-title":"Front Endocrinol"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2274","DOI":"10.3390\/biomedicines10092274","article-title":"Coronary microvascular dysfunction in diabetes mellitus: pathogenetic mechanisms and potential therapeutic options","volume":"10","author":"Salvatore","year":"2022","journal-title":"Biomedicines"},{"key":"B63","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular dysfunction in diabetes mellitus and cardiometabolic disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr Rev"},{"key":"B64","doi-asserted-by":"publisher","first-page":"112857","DOI":"10.1016\/j.yexcr.2021.112857","article-title":"Involvement of multiple scavenger receptors in advanced glycation end product-induced vessel tube formation in endothelial cells","volume":"408","author":"Yamazaki","year":"2021","journal-title":"Exp Cell Res"},{"key":"B65","doi-asserted-by":"publisher","first-page":"1251780","DOI":"10.3389\/fcvm.2024.1251780","article-title":"The inflammatory spectrum of cardiomyopathies","volume":"11","author":"Musigk","year":"2024","journal-title":"Front Cardiovasc Med"},{"key":"B66","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1111\/dom.16242","article-title":"Mechanisms of diabetic cardiomyopathy: focus on inflammation","volume":"27","author":"Bellemare","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"B67","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1038\/s41467-020-15978-3","article-title":"MD2 Activation by direct AGE interaction drives inflammatory diabetic cardiomyopathy","volume":"11","author":"Wang","year":"2020","journal-title":"Nat Commun"},{"key":"B68","doi-asserted-by":"publisher","first-page":"255","DOI":"10.24875\/GMM.22000403","article-title":"NLRP3 Inflammasome mechanism and therapeutic targets in diabetic cardiomyopathy","volume":"159","author":"Sun","year":"2023","journal-title":"Gac Med Mex"},{"key":"B69","doi-asserted-by":"publisher","first-page":"20420188221083530","DOI":"10.1177\/20420188221083530","article-title":"Role of inflammation in diabetic cardiomyopathy","volume":"13","author":"Ramesh","year":"2022","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B70","doi-asserted-by":"publisher","first-page":"1162754","DOI":"10.3389\/fendo.2023.1162754","article-title":"Central role of cardiac fibroblasts in myocardial fibrosis of diabetic cardiomyopathy","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Endocrinol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/ijms21030970","article-title":"The diabetic cardiac fibroblast: mechanisms underlying phenotype and function","volume":"21","author":"Levick","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B72","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1096\/fj.02-1117fje","article-title":"Advanced glycation end products activate Smad signaling via transforming growth factor-beta-dependent and independent mechanisms: implications for diabetic renal and vascular disease","volume":"18","author":"Li","year":"2004","journal-title":"FASEB J"},{"key":"B73","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrneph.2016.48","article-title":"TGF-\u03b2: the master regulator of fibrosis","volume":"12","author":"Meng","year":"2016","journal-title":"Nat Rev Nephrol"},{"key":"B74","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41569-023-00946-3","article-title":"The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases","volume":"21","author":"Toldo","year":"2024","journal-title":"Nat Rev Cardiol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"826","DOI":"10.14336\/AD.2020.1217","article-title":"CD36 Signaling in diabetic cardiomyopathy","volume":"12","author":"Zhang","year":"2021","journal-title":"Aging Dis"},{"key":"B76","doi-asserted-by":"publisher","first-page":"222","DOI":"10.4239\/wjd.v14.i3.222","article-title":"N\u03b5-(carboxymethyl)lysine promotes lipid uptake of macrophage via cluster of differentiation 36 and receptor for advanced glycation end products","volume":"14","author":"Wang","year":"2023","journal-title":"World J Diabetes"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2042018819834869","DOI":"10.1177\/2042018819834869","article-title":"Diabetic cardiomyopathy: prevalence, determinants and potential treatments","volume":"10","author":"Gulsin","year":"2019","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/eurheartj\/ehv134","article-title":"Clinical diabetic cardiomyopathy: a two-faced disease with restrictive and dilated phenotypes","volume":"36","author":"Seferovi\u0107","year":"2015","journal-title":"Eur Heart J"},{"key":"B79","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.3390\/biomedicines12092153","article-title":"Role of circulating biomarkers in diabetic cardiomyopathy","volume":"12","author":"Iano\u0219","year":"2024","journal-title":"Biomedicines"},{"key":"B80","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1186\/s12902-024-01759-2","article-title":"Association between the soluble receptor for advanced glycation end products and diabetes mellitus: systematic review and meta-analysis","volume":"24","author":"Chen","year":"2024","journal-title":"BMC Endocr Disord"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12933-025-03019-6","article-title":"Cardiac MRI in diabetic cardiomyopathy: translating imaging biomarkers into clinical practice","volume":"25","author":"Huang","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1405031","DOI":"10.3389\/fendo.2024.1405031","article-title":"The role of multimodality imaging in diabetic cardiomyopathy: a brief review","volume":"15","author":"Chen","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1186\/s12933-025-02955-7","article-title":"Cardiometabolic HFpEF with focus on type 2 diabetes mellitus","volume":"24","author":"Gorica","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1038\/s41598-024-52101-8","article-title":"The WATCH-DM risk score estimates clinical outcomes in type 2 diabetic patients with heart failure with preserved ejection fraction","volume":"14","author":"Iwakura","year":"2024","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00125-014-3171-6","article-title":"Molecular mechanisms of diabetic cardiomyopathy","volume":"57","author":"Bugger","year":"2014","journal-title":"Diabetologia"},{"key":"B86","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1161\/CIRCRESAHA.118.311371","article-title":"Heart failure in type 2 diabetes mellitus","volume":"124","author":"Kenny","year":"2019","journal-title":"Circ Res"},{"key":"B87","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.3390\/ijms23073439","article-title":"The role of advanced glycation end products and its soluble receptor in kidney diseases","volume":"23","author":"Steenbeke","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B89","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12933-025-03017-8","article-title":"Soluble RAGE further stratifies risk of coronary artery and end-stage kidney disease in high-risk individuals with type 1 diabetes and treatment-resistant hypertension","volume":"25","author":"Adeshara","year":"2026","journal-title":"Cardiovasc Diabetol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.1944","article-title":"Risk of bias in studies investigating novel diagnostic biomarkers for heart failure with preserved ejection fraction: a systematic review","volume":"22","author":"Henkens","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"B91","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.amjmed.2024.10.026","article-title":"Diabetic cardiomyopathy: what clinicians should know","volume":"138","author":"Smati","year":"2025","journal-title":"Am J Med"},{"key":"B92","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1186\/s13098-025-01986-0","article-title":"Diabetic cardiomyopathy: a comprehensive review of diagnosis, management, and future directions","volume":"17","author":"Balakrishnan","year":"2025","journal-title":"Diabetol Metab Syndr"},{"key":"B93","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41392-024-01760-0","article-title":"New clinical trial design in precision medicine: discovery, development and direction","volume":"9","author":"Duan","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1501735","DOI":"10.3389\/fcvm.2024.1501735","article-title":"Advances of research in diabetic cardiomyopathy: diagnosis and the emerging application of sequencing","volume":"11","author":"He","year":"2025","journal-title":"Front Cardiovasc Med"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/S0140-6736(23)02756-3","article-title":"Heart failure with preserved ejection fraction: everything the clinician needs to know","volume":"403","author":"Campbell","year":"2024","journal-title":"Lancet"},{"key":"B96","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1001\/jamacardio.2022.1916","article-title":"Diagnosis of heart failure with preserved ejection fraction among patients with unexplained dyspnea","volume":"7","author":"Reddy","year":"2022","journal-title":"JAMA Cardiol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"114211","DOI":"10.1016\/j.biopha.2022.114211","article-title":"Pyridoxamine prevents increased atherosclerosis by intermittent methylglyoxal spikes in the aortic arches of ApoE-\/- mice","volume":"158","author":"Hanssen","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B98","doi-asserted-by":"publisher","first-page":"e202300503","DOI":"10.1002\/cbic.202300503","article-title":"Modulating the RAGE-induced inflammatory response: peptoids as RAGE antagonists","volume":"24","author":"Waugh","year":"2023","journal-title":"Chembiochem"},{"key":"B99","doi-asserted-by":"publisher","first-page":"9932311","DOI":"10.1155\/2021\/9932311","article-title":"DNA-aptamer raised against receptor for advanced glycation end products improves survival rate in septic mice","volume":"2021","author":"Koga","year":"2021","journal-title":"Oxid Med Cell Longev"},{"key":"B100","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/2012","article-title":"Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation end products","volume":"4","author":"Park","year":"1998","journal-title":"Nat Med"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e71173","DOI":"10.1096\/fj.202502255RR","article-title":"A soluble receptor for advanced glycation end-products attenuates myocardial ischemia\/reperfusion injury via enhancing glucose metabolism","volume":"39","author":"Wu","year":"2025","journal-title":"FASEB J"},{"key":"B102","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13578-025-01482-y","article-title":"sRAGE inhibits myocardial ischemia\/reperfusion injuries via regulating treg cells","volume":"15","author":"Liu","year":"2025","journal-title":"Cell Biosci"},{"key":"B103","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1007\/s10495-022-01724-1","article-title":"Integrin\u03b23 mediates the protective effects of soluble receptor for advanced glycation end-products during myocardial ischemia\/reperfusion through AKT\/STAT3 signaling pathway","volume":"27","author":"Han","year":"2022","journal-title":"Apoptosis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"117304","DOI":"10.1016\/j.atherosclerosis.2023.117304","article-title":"RAGE\/DIAPH1 and atherosclerosis through an evolving lens: viewing the cell from the \u201cinside-out\u201d","volume":"394","author":"Ramasamy","year":"2024","journal-title":"Atherosclerosis"},{"key":"B105","doi-asserted-by":"publisher","first-page":"501","DOI":"10.26502\/jbb.2642-91280112","article-title":"Discovery of potential RAGE inhibitors using receptor-based pharmacophore modeling, high throughput virtual screening and docking studies","volume":"6","author":"Singh","year":"2023","journal-title":"J Biotechnol Biomed"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1724965","DOI":"10.3389\/fendo.2025.1724965","article-title":"Mechanism-guided pharmacotherapy for cardiometabolic multimorbidity: from pathophysiology to phenotype-prioritized treatment","volume":"16","author":"Dong","year":"2025","journal-title":"Front Endocrinol"},{"key":"B107","doi-asserted-by":"publisher","first-page":"7","DOI":"10.33963\/v.phj.110057","article-title":"Practical approach to the management of diabetic cardiomyopathy: from molecular pathways to treatment strategies","volume":"84","author":"Prieto-La\u00edn","year":"2025","journal-title":"Pol Heart J"},{"key":"B108","doi-asserted-by":"publisher","first-page":"113116","DOI":"10.1016\/j.diabres.2026.113116","article-title":"Heart failure with preserved ejection fraction (HFpEF): translational mechanisms, diagnostic evolution and therapeutic frontiers","volume":"232","author":"Gao","year":"2026","journal-title":"Diabetes Res Clin Pract"},{"key":"B109","doi-asserted-by":"publisher","first-page":"11043","DOI":"10.1038\/s41598-023-37678-w","article-title":"Artemisinin attenuates type 2 diabetic cardiomyopathy in rats through modulation of AGE-RAGE\/HMGB-1 signaling pathway","volume":"13","author":"Farrag","year":"2023","journal-title":"Sci Rep"},{"key":"B110","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s10020-024-00905-9","article-title":"Advanced glycation end products and reactive oxygen species: uncovering the potential role of ferroptosis in diabetic complications","volume":"30","author":"Chen","year":"2024","journal-title":"Mol Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1016\/j.bbadis.2015.07.015","article-title":"Cardiomyocyte-fibroblast interaction contributes to diabetic cardiomyopathy in mice: role of HMGB1\/TLR4\/IL-33 axis","volume":"1852","author":"Tao","year":"2015","journal-title":"Biochim Biophys Acta Mol Basis Dis"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1846184\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T12:30:18Z","timestamp":1787229018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1846184\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,20]]},"references-count":111,"alternative-id":["10.3389\/fcvm.2026.1846184"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1846184","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,20]]},"article-number":"1846184"}}